Latest news with #JasonTurner
Medscape
27-06-2025
- Health
- Medscape
New Data at EULAR Signal Advances in RA, Myopathy, Gout
Barcelona has become the world capital of rheumatology by hosting the 2025 Annual Meeting of the European Alliance of Associations for Rheumatology (EULAR) in Spain. 'This is the world's largest rheumatology event,' said Daniel Aletaha, MD, president of EULAR and head of the Department of Rheumatology at the University Clinic for Internal Medicine III, MedUni Vienna, Vienna, Austria, during the conference opening session. He highlighted the scale of participation: 5125 abstracts submitted from 95 countries, 117 sessions, and 350 speakers from 45 nations. Inflammatory and Autoimmune Disease Among the plenary highlights was research led by Jason D. Turner, PhD, a postdoctoral research fellow at the University of Birmingham, Birmingham, England. His comparative analysis of synovial tissue using single-cell and spatial transcriptomics identified overlapping disease pathways in spontaneous inflammatory arthritis and arthritis induced by immune checkpoint inhibitors. 'We found that the synovium in checkpoint inhibitor-associated arthritis is enriched with fibroblasts and T cells, is highly vascularised, and contains large numbers of CXCL9/10/11+ macrophages and CD8+ T cells. These findings support the current use of tumour necrosis factor inhibitors for this condition, although further investigation is needed to understand their applicability to spontaneous arthritis,' Turner explained. Hector Chinoy, PhD, FRCP, professor of rheumatology at the University of Manchester and lead at the Salford Royal Adult Neuromuscular Service, Manchester, England, presented the results of the ALKIVIA phase 2 study. This trial evaluated the efficacy of subcutaneous efgartigimod (PH20) administration in adults with active idiopathic inflammatory myopathy. The drug led to significant improvements in the Total Improvement Score compared with placebo and showed good tolerability and safety. 'These findings demonstrate the mechanistic importance of neonatal Fc receptor inhibition and suggest a potential pathogenic role for autoantibodies. These findings support the continued evaluation of the drug in the ongoing phase 3 trial' Chinoy said. Scleroderma, Preclinical Rheumatoid Arthritis (RA), Gout, and Lupus Adela‑Cristina Sarbu, MD, a researcher specialising in systemic sclerosis and interstitial lung disease at the University Hospital Bern, Bern, European Scleroderma Trials and Research group (EUSTAR), and the University of Zurich, Zurich, Switzerland, presented the findings from the EUSTAR cohort. In conclusion, exposure to prostanoids appeared to be associated with a slower progression of interstitial lung disease in patients with mild vascular disease. In contrast, exposure to endothelin receptor antagonists appeared to be beneficial in preventing symptom worsening in patients with more severe vascular diseases. 'No independent mortality benefit was seen with vasoactive or vasodilator drugs. Their effectiveness seems to depend on the severity of vascular disease' Sarbu noted, calling for further long-term studies. The ALTO study, an extension of the APIPPRA trial, led by Andrew Cope, PhD, of King's College London, London, England, found that a 1-year course of abatacept in individuals at high risk of developing RA could delay disease onset by up to 4 years. 'Individuals with baseline autoantibody profiles are more likely to develop the disease and respond well to T-cell co-stimulation blockade. Abatacept reduces the symptom burden during treatment but does not provide sustained benefits after treatment discontinuation. No new safety concerns were reported,' according to Cope. Edoardo Cipolletta, MD, rheumatologist at the Marche University Hospital, Ancona, Italy, and research associate at the University of Nottingham, Nottingham, England, presented an analysis of data on primary care, hospitalization, and mortality outcomes related to gout, based on cohorts from the UK and Sweden. The study found that achieving serum urate levels below 360 µmol/L within a year of initiating urate-lowering treatment was associated with a significantly lower risk for major adverse cardiovascular events. The 5-year relative risk reduction ranged from 6% to 11%, with an absolute survival benefit of 1.3%-1.4%. 'The association was consistent regardless of prior cardiovascular disease and across all sensitivity analyses,' Cipolletta reported. Richard A. Furie, MD, chief of Rheumatology at Northwell Health in New York, presented results from the REGENCY study, which evaluated obinutuzumab in patients with lupus nephritis. Award Recognition Miriam Ruiz Ponce, MSc, a predoctoral researcher at the Maimonides Biomedical Research Institute in Córdoba, Spain received one of the EULAR award for translational basic science. She developed a mouse model of fatty liver disease associated with inflammatory arthritis to evaluate the anti-inflammatory and metabolic properties of apremilast, a drug commonly used in psoriatic arthritis. 'Early results have shown that the drug has promising effects, as it partially reverses liver damage, as well as inflammation. These are the initial results, but it could be a potential treatment for inflammation and for the deleterious effects on the liver in these patients. It is an honour to receive this award, which motivates us to continue our research under the leadership of my mentor, Nuria Barbarroja Puerto, PhD, the principal investigator of the potential treatment targeting inflammation and liver damage,' she said. Chinoy disclosed financial relationships with AstraZeneca, Pfizer, PTC Therapeutics, and UCB. Furie disclosed the financial relationships with GSK and Genentech; the REGENCY study was funded by F. Hoffmann-La Roche. Sarbu and Cope disclosed having no relevant financial relationships. Turner, Cipolletta, and Ponce did not provide conflict-of-interest disclosures.
Yahoo
09-06-2025
- Business
- Yahoo
Meharry Medical College to expand into Memphis, partners with Mississippi Boulevard church
Meharry Medical College is set to expand into Memphis with a new medical training facility. The historically Black, Nashville-based medical school announced the formation of its 'Office of Memphis Programs' at a ribbon-cutting on June 9. The new program will be housed on the planned 23-acre mixed-use campus of Mississippi Boulevard Christian Church in the Medical District and will support students during clinical training. 'I see this as a wonderful opportunity to turn the tide on and bring about better health care outcomes in the city of Memphis,' said Rev. Jason Turner of Mississippi Boulevard church. The expansion is part of Meharry's long-term goal of building a second campus in Memphis, said CEO and president James Hildreth. The college often has to send students to hospitals out of state because major hospitals in Nashville have commitments to training students from other schools. 'One of the things that the branch campus in Memphis will do for us is to allow us to have two major training sites and not have to send our students to so many places,' he said. The new facility will feature classrooms, faculty offices and a student lounge. The quality of education will be the same as at the main campus in Nashville, Hildreth said, but it will lay the foundation for a branch campus and keep medical students in Tennessee. Memphis has one of the highest rates of HIV/AIDS in the country and struggles with obesity and diabetes, Hildreth said. He said Meharry plans to focus on the burden of chronic diseases in the city. 'Memphis is a place where we can have a huge impact,' Hildreth said. In April, Meharry acquired four medical clinics in Memphis. A Meharry alumnus, Dr. Joseph Walker, founded Mississippi Boulevard Christian Church in 1921. He was its first pastor. 'It's serendipitous that their Office of Memphis Programs would be housed in the church that he founded 104 years ago,' Turner said. Jack Armstrong covers breaking news and the environment for The Commercial Appeal. He can be reached at and followed on X @jca2902. This article originally appeared on Memphis Commercial Appeal: Meharry Medical College part of Mississippi Boulevard Memphis expansion
Yahoo
13-05-2025
- Business
- Yahoo
Oracle Partners With seQure To Bolster Cybersecurity For Governments, Enterprises
Oracle Corporation (NYSE:ORCL), along with seQure, a cybersecurity firm and its partner, disclosed the availability of seQure's Ground-Truth service on Oracle Cloud Infrastructure (OCI). The company said that Ground-Truth is a cybersecurity and data observability service that helps automate the detection of threats and vulnerabilities and can reduce event alerts by 90%. Previously an on-premises solution, Ground-Truth can now be deployed across Oracle's various cloud offerings, including public, government, sovereign, and dedicated cloud with Oracle's security framework allows seQure to offer customers sophisticated, AI-powered threat detection while meeting data localization needs. This enables operational flexibility in intricate environments, compliance with regulatory, security, and performance standards, and unlocks the complete advantages of cloud and sovereign AI capabilities. Rand Waldron, vice president, Oracle said, 'This partnership helps our combined customers identify unknown cyber threats and anomalies faster and more accurately. In addition, it enables customers to benefit from OCI's built-in security, leading performance, and flexibility.' Jason Turner, chairman and CEO Entanglement stated, 'OCI's high-performance infrastructure and scaling was essential for deploying this solution and enabling us to provide our customers with the benefits of automated scaling, robust security features, and predictable pricing.' Last week, IBM disclosed a collaboration with Oracle to integrate IBM's premier AI platform, Watsonx, with Oracle Cloud Infrastructure (OCI). Investors can gain exposure to the stock via Pacer Funds Pacer Data and Digital Revolution ETF (NYSE:TRFK) and iShares Expanded Tech-Software Sector ETF (BATS:IGV). Price Action: ORCL shares are up 0.70% at $158.32 at the last check on Tuesday. Image by Mdisk via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? ORACLE (ORCL): Free Stock Analysis Report This article Oracle Partners With seQure To Bolster Cybersecurity For Governments, Enterprises originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
